Covid-19 roundup: Mod­er­na, US sign con­tract for au­tumn boost­er dos­es; Enan­ta touts PhI re­sults for its an­tivi­ral

The US gov­ern­ment has placed a con­tract for 66 mil­lion dos­es of Mod­er­na’s Covid-19 vac­cine boost­er can­di­date, and the deal could bal­loon to an­oth­er 234 mil­lion dos­es.

The con­tract in­cludes up to $1.74 bil­lion for Mod­er­na to man­u­fac­ture and de­liv­er the dos­es of the bi­va­lent vac­cine can­di­date, dubbed mR­NA-1273.222. The shot con­tains anti­gens against the BA.4/BA.5 Omi­cron sub­vari­ant strains and is part of Mod­er­na’s ef­fort to de­liv­er a boost­er shot this au­tumn, pend­ing the nec­es­sary go-ahead from the FDA and CDC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER